Quotes 5-day view Delayed Nasdaq
04/12/2021
04/13/2021
04/14/2021
04/15/2021
04/16/2021
Date
100.53(c)
106.59(c)
107.97(c)
109.58(c)
108.72(c)
Last
556 049
456 572
251 681
208 910
376 430
Volume
-2.85%
+6.03%
+1.29%
+1.49%
-0.78%
Change
Sales 2021
329 M
-
-
Net income 2021
-354 M
-
-
Net cash position 2021
813 M
-
-
P/E ratio 2021
-20,4x
Yield 2021
-
Sales 2022
414 M
-
-
Net income 2022
-324 M
-
-
Net cash position 2022
621 M
-
-
P/E ratio 2022
-24,2x
Yield 2022
-
Capitalization
7 279 M
7 279 M
-
EV / Sales 2021
19,7x
EV / Sales 2022
16,1x
Nbr of Employees
893
Free-Float
94,7%
Ultragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies....
Notations Surperformance© of Ultragenyx Pharmaceutical Inc.
Trading Rating :
Investor Rating :
All news about ULTRAGENYX PHARMACEUTICAL INC.
News in other languages on ULTRAGENYX PHARMACEUTICAL INC.
- No features available -
Analyst Recommendations on ULTRAGENYX PHARMACEUTICAL INC.
ULTRAGENYX PHARMACEUTICAL INC. - 2020
The underlying trend is in force again
BUY
Chart ULTRAGENYX PHARMACEUTICAL INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends ULTRAGENYX PHARMACEUTICAL INC.
Short Term Mid-Term Long Term Trends Bearish Neutral Neutral
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
15
Average target price
160,19 $
Last Close Price
108,72 $
Spread / Highest target
79,4%
Spread / Average Target
47,3%
Spread / Lowest Target
-8,94%
Please enable JavaScript in your browser's settings to use dynamic charts.